XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
The aim of this study is to evaluate efficacy and safety of Capecitabine/Cisplatin for
 gastric cancer patients who relapsed after adjuvant chemotherapy by S-1.
S-1/Cisplatin (SP) is one of the standard treatments of advanced gastric cancer. However,
 evidence of SP on gastric cancer recurrence after adjuvant therapy by the same drug (S-1) is
 not established. The aim of this study is to evaluate the efficacy and safety of
 Capecitabine/Cisplatin (XP) for gastric cancer patients who relapsed after adjuvant
 chemotherapy by S-1.
Inclusion Criteria:

 1. Recurrent gastric cancer histologically confirmed as being adenocarcinoma

 2. Age of 20 to 74 years with either gender

 3. ECOG Performance Status of 0 to 2

 4. Lesions confirmed on imaging within 28 days before registration (not required
 measurable lesions as defined in RECIST version 1.1)

 5. Post-gastrectomy adjuvant chemotherapy including S-1 for at least 12 weeks including
 interruption period

 6. Less than 6 months treatment-free interval from completion of adjuvant therapy

 7. In case with receiving neoadjuvant chemotherapy, the total dose of CDDP does not
 exceed 120mg/m2

 8. Treatment-naïve recurrent gastric cancer

 9. Life expectancy of at least 3 months after registration

 10. Written informed consent

 11. Adequate major organ functions within 14 days before registration

 Exclusion Criteria:

 12. Positive HER2 status

 13. Previous treatment with platinum agents after curative surgery

 14. Previous history of serious hypersensitivity to fluoropyrimidines or platinum agents

 15. Previous history of adverse reactions suggestive of dihydropyrimidine dehydrogenase
 (DPD) deficiency

 16. More than one cancer at the same time or more than one cancer at different times
 separated by a 5-year disease-free interval. However, multiple active cancers do not
 include carcinoma in situ or skin cancer which is determined to have been cured as a
 result of treatment.

 17. Obvious infection or inflammation (pyrexia ≥ 38.0˚C)

 18. Active hepatitis

 19. Heart disease that is serious or requires hospitalization, or history of such disease
 within past year

 9) Concurrent illness that is serious or requires hospitalization (intestinal paralysis,
 intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, poorly controlled
 diabetes mellitus, renal failure, liver disorders, or hepatic cirrhosis)

 10) Being treated or in need of treatment with phenytoin or warfarin potassium

 11) Chronic diarrhea (watery stool or ≥ 4 times/day)

 12) Active gastrointestinal hemorrhage

 13) Body cavity fluids requiring drainage or other treatment

 14) Clinical suspicion or previous history of metastases to brain or meninges

 15) Women who are pregnant, breastfeeding, or potentially (hoping to become) pregnant 16)
 Unwillingness to practice contraception

 17) Poor oral intake

 18) Psychiatric disorders which are being or may need to be treated with psychotropics

 19) Otherwise determined by investigators or site principal investigators to be unsuitable
 for participation in study